RxDoctor Payments Data

Soubhi Azar, MD

Internal Medicine · Manlius, NYNPI 1457646341

Payments from drug & device makers

$720in general payments, 2019–2025

Across 54 payments — averaging $13.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$202
  • Novo Nordisk$192
  • Amarin Pharma, Inc.$79
  • Pfizer$52
  • Astellas Pharma US Inc$49
  • Lilly USA, LLC$32
  • plus $115 from 6 others

What the payments were for

  • Food & beverage$720100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$720 in reported general payments places this provider in the 65th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$93,715
Medicare patients
198
Services billed
1,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin64$76,365
OzempicSemaglutide44$63,155
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$55,524
EliquisApixaban56$45,571
JanuviaSitagliptin Phosphate25$20,625
MounjaroTirzepatide15$15,232
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$14,748
XareltoRivaroxaban14$12,995
TradjentaLinagliptin16$12,148
Repatha SyringeEvolocumab17$12,071
Breo ElliptaFluticasone/Vilanterol19$10,482
Icosapent Ethyl24$8,377
Atorvastatin Calcium488$4,062
VascepaIcosapent Ethyl11$3,919
Levothyroxine Sodium224$3,617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$30$88,51380 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$202$83,89299 claims
Novo NordiskOzempic$192$63,15544 claims
PfizerEliquis$52$45,57156 claims
MerckJanuvia$11$20,62525 claims
Lilly USA, LLCMounjaro$32$15,23215 claims
Johnson & JohnsonXarelto$24$12,99514 claims
AbbVieSynthroid$16$84819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Manlius

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →